EJNMMI Radiopharmacy and Chemistry (Sep 2023)

Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β

  • Olivia Wegrzyniak,
  • Bo Zhang,
  • Johanna Rokka,
  • Maria Rosestedt,
  • Bogdan Mitran,
  • Pierre Cheung,
  • Emmi Puuvuori,
  • Sofie Ingvast,
  • Jonas Persson,
  • Helena Nordström,
  • John Löfblom,
  • Fredrik Pontén,
  • Fredrik Y. Frejd,
  • Olle Korsgren,
  • Jonas Eriksson,
  • Olof Eriksson

DOI
https://doi.org/10.1186/s41181-023-00210-6
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Background Platelet-derived growth factor receptor beta (PDGFRβ) is a receptor overexpressed on activated hepatic stellate cells (aHSCs). Positron emission tomography (PET) imaging of PDGFRβ could potentially allow the quantification of fibrogenesis in fibrotic livers. This study aims to evaluate a fluorine-18 radiolabeled Affibody molecule ([18F]TZ-Z09591) as a PET tracer for imaging liver fibrogenesis. Results In vitro specificity studies demonstrated that the trans-Cyclooctenes (TCO) conjugated Z09591 Affibody molecule had a picomolar affinity for human PDGFRβ. Biodistribution performed on healthy rats showed rapid clearance of [18F]TZ-Z09591 through the kidneys and low liver background uptake. Autoradiography (ARG) studies on fibrotic livers from mice or humans correlated with histopathology results. Ex vivo biodistribution and ARG revealed that [18F]TZ-Z09591 binding in the liver was increased in fibrotic livers (p = 0.02) and corresponded to binding in fibrotic scars. Conclusions Our study highlights [18F]TZ-Z09591 as a specific tracer for fibrogenic cells in the fibrotic liver, thus offering the potential to assess fibrogenesis clearly. Graphical abstract

Keywords